|Bid||4.5200 x 993000|
|Ask||4.5300 x 862200|
|Day's range||4.4400 - 4.6500|
|52-week range||3.5500 - 8.8200|
|Beta (5Y monthly)||2.28|
|PE ratio (TTM)||N/A|
|Earnings date||17 Aug 2022 - 22 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.15|
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial intelligence (AI) platform to accompany Telix's PSMA-PET imaging agent, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide) - known as TelixAITM.
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in the Jubilant Radiopharma network. Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use of Telix's prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide) with the RefleXion® biology-guided radiotherapy (BgRT)* platform to guide external-beam radiotherapy in real-time.